Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionAnti-TIM3 checkpoint inhibitor
Molecular Target T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today